Karin Bowen

4.0k total citations · 3 hit papers
30 papers, 2.8k citations indexed

About

Karin Bowen is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Oncology. According to data from OpenAlex, Karin Bowen has authored 30 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 20 papers in Physiology and 6 papers in Oncology. Recurrent topics in Karin Bowen's work include Asthma and respiratory diseases (20 papers), Respiratory and Cough-Related Research (8 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Karin Bowen is often cited by papers focused on Asthma and respiratory diseases (20 papers), Respiratory and Cough-Related Research (8 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Karin Bowen collaborates with scholars based in United States, United Kingdom and Sweden. Karin Bowen's co-authors include Gene Colice, Michael Friedländer, Anitra Fielding, Georgeta Fried, Judith Balmañà, Gillian Mitchell, Ronnie Shapira‐Frommer, Susan M. Domchek, M. William Audeh and Bella Kaufman and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Karin Bowen

27 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

2014 1.2k citations Bella Kaufman, Ronnie Shapira‐Frommer et al. Journal of Clinical Oncology profile →
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma

2021 606 citations Andrew Menzies‐Gow, Jonathan Corren et al. profile →
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials

2023 95 citations Jonathan Corren, Andrew Menzies‐Gow et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karin Bowen United States	15	1.3k	1.0k	942	809	502	30	2.8k
James D. Reimann United States	12	967 0.8×	1.1k 1.1×	813 0.9×	607 0.8×	340 0.7×	16	3.0k
Sebastian Aulmann Germany	31	910 0.7×	238 0.2×	795 0.8×	1.0k 1.2×	151 0.3×	74	2.4k
Yasuyuki Hirashima Japan	26	542 0.4×	71 0.1×	184 0.2×	557 0.7×	114 0.2×	81	1.8k
I. J. Christensen Denmark	24	1.2k 0.9×	55 0.1×	285 0.3×	460 0.6×	213 0.4×	49	2.2k
Raji Ganesan United Kingdom	30	428 0.3×	50 0.0×	489 0.5×	547 0.7×	230 0.5×	112	3.1k
Randeep Sangha Canada	23	1.3k 1.0×	121 0.1×	542 0.6×	590 0.7×	330 0.7×	72	2.3k
Fabienne Meggetto France	24	971 0.8×	248 0.2×	196 0.2×	593 0.7×	338 0.7×	60	2.0k
Jane Robertson United Kingdom	22	1.3k 1.0×	83 0.1×	510 0.5×	816 1.0×	174 0.3×	57	2.0k
Ulrika Stierner Sweden	32	1.1k 0.9×	26 0.0×	422 0.4×	911 1.1×	450 0.9×	81	2.6k
Mária Dudás United States	18	650 0.5×	67 0.1×	822 0.9×	806 1.0×	69 0.1×	22	2.0k

Countries citing papers authored by Karin Bowen

Since Specialization

Citations

This map shows the geographic impact of Karin Bowen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Bowen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Bowen more than expected).

Fields of papers citing papers by Karin Bowen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Bowen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Bowen. The network helps show where Karin Bowen may publish in the future.

Co-authorship network of co-authors of Karin Bowen

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Bowen. A scholar is included among the top collaborators of Karin Bowen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Bowen. Karin Bowen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Martinez, Fernando J., John R. Hurst, MeiLan K. Han, et al.. (2025). Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial. ERJ Open Research. 11(6). 324–2025.

Bafadhel, Mona, Jonathan Marshall, Himanshu Parikh, et al.. (2025). Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS. Respiratory Research. 26(1). 175–175.

Muro, Shigeo, Tomotaka Kawayama, Hisatoshi Sugiura, et al.. (2024). Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history. Respiratory Research. 25(1). 297–297. 1 indexed citations

Muro, Shigeo, John R. Hurst, Jonathan Marshall, et al.. (2024). Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS. International Journal of COPD. Volume 19. 2729–2737.

Singh, Dave, Fernando J. Martínez, John R. Hurst, et al.. (2024). Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS). American Journal of Respiratory and Critical Care Medicine. 211(2). 205–214. 10 indexed citations

Corren, Jonathan, Andrew Menzies‐Gow, Geoffrey Chupp, et al.. (2023). Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. American Journal of Respiratory and Critical Care Medicine. 208(1). 13–24. 95 indexed citations breakdown →

Ambrose, Christopher S., Elliot Israel, Karin Bowen, et al.. (2023). Reply to Lipworth and Chan. American Journal of Respiratory and Critical Care Medicine. 208(2). 212–213. 1 indexed citations

Corren, Jonathan, et al.. (2021). Efficacy of tezepelumab in patients with low and high bronchodilator reversibility in PATHWAY. Pneumologie. 1 indexed citations

Emson, Claire, Sarah Diver, Latifa Chachi, et al.. (2020). CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma. Respiratory Research. 21(1). 265–265. 25 indexed citations

10.

Wechsler, Michael E., Gene Colice, Janet M. Griffiths, et al.. (2020). SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respiratory Research. 21(1). 264–264. 60 indexed citations

11.

Menzies‐Gow, Andrew, Sandhia Ponnarambil, John Downie, et al.. (2020). DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respiratory Research. 21(1). 279–279. 45 indexed citations

12.

Menzies‐Gow, Andrew, Gene Colice, Janet M. Griffiths, et al.. (2020). NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respiratory Research. 21(1). 266–266. 70 indexed citations

13.

Corren, Jonathan, et al.. (2020). Efficacy of tezepelumab in patients with low and high bronchodilator reversibility in PATHWAY. 2269–2269. 1 indexed citations

14.

Gottlow, Mattis, et al.. (2019). Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma. BMC Pulmonary Medicine. 19(1). 129–129. 9 indexed citations

15.

Panettieri, Reynold A., Ulf Sjöbring, Peter Wessman, et al.. (2018). Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. The Lancet Respiratory Medicine. 6(7). 511–525. 177 indexed citations

16.

Brusselle, Guy, Stephanie Korn, Piotr Kuna, et al.. (2018). Oral corticosteroid (OCS)-sparing effect of tralokinumab in severe, uncontrolled asthma: the TROPOS study. PA602–PA602. 2 indexed citations

17.

Soria, J.C., Carlos Dias Maciel, Jürgen R. Fischer, et al.. (2017). SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Annals of Oncology. 28(12). 3028–3036. 24 indexed citations

18.

Jänne, Pasi A., Michel M. van den Heuvel, Fabrice Barlési, et al.. (2017). Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer. JAMA. 317(18). 1844–1844. 249 indexed citations

19.

Jänne, Pasi A., Michel M. van den Heuvel, Fabrice Barlési, et al.. (2016). Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial. Annals of Oncology. 27. vi583–vi583. 10 indexed citations

20.

Kaufman, Bella, Ronnie Shapira‐Frommer, Rita K. Schmutzler, et al.. (2013). Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study.. Journal of Clinical Oncology. 31(15_suppl). 11024–11024. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact